Fourteen million people in the United States have diabetes mellitus, and diabetic nephropathy is, not surprisingly, the country's leading cause of end-stage renal disease. 1, 2 Microalbuminuria is considered a marker of incipient nephropathy in people with diabetes, and, thus, screening for microalbuminuria is performed routinely in people with type 1 and type 2 diabetes. [3] [4] [5] Microalbuminuria refers to urinary albumin excretion that is more than the normal range but less than levels that can be detected by a urine dipstick. 6 Microalbuminuria is defined as 30 to 300 mg of albumin in a 24-hour urine sample or an albumin/creatinine ratio (ACR) of 0.03 to 0.3 in a random urine sample, preferably the first morning void. 3, 7 If microalbuminuria is detected early in patients with diabetes, the onset of nephropathy and cardiovascular disease can be prevented with drugs that inhibit the renal angiotensin-aldosterone system. [8] [9] [10] [11] [12] [13] It is interesting that prospective studies have demonstrated that microalbuminuria can predict cardiovascular disease and premature mortality in hypertensive patients and even in the general population. 6, 12, 13 It is postulated that microalbuminuria is associated with nephropathy and cardiovascular disease because it is an indicator of generalized vascular dysfunction. In addition, microalbuminuria itself may damage the kidney by inducing production of inflammatory agents. 12 Most commercially available tests to quantify urinary albumin are immunoassays, such as immunoturbidimetry, immunonephelometry, and radioimmunoassay. 14 The immunochemical methods are sensitive, but recent studies suggest that after glomerular filtration, some albumin may be processed by lysosomes to create an immunounreactive form of intact albumin that cannot be detected by immunoassays. 15 High-performance liquid chromatography (HPLC) and gel electrophoresis have the ability to detect immunoreactive and immunounreactive albumin, [16] [17] [18] [19] but neither is practical in most clinical laboratory settings. Also, a recent study with size-exclusion HPLC demonstrated that other urinary proteins coelute with albumin, making the accuracy of HPLC debatable. 20 A simple and cost-effective assay that offers a sensitive, accurate, and precise measurement of all forms of intact urinary albumin must be established because the current immunoassays may be underestimating the amount of urinary albumin. We developed a chip-based assay to measure microalbuminuria using the P200 protein chip (Caliper Life Sciences, Mountain View, CA, and Agilent Technologies, Santa Clara, CA) and 2100 Bioanalyzer (Agilent Technologies), which integrates and automates the steps of sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). We tested the assay for linearity, precision, and accuracy. Owing to the impracticality of doing HPLC and gel electrophoresis in most clinical laboratories and the questionable accuracy of HPLC, we focused our investigation on comparing the chip assay with a commonly used immunoturbidimetric method for quantifying albumin in urine samples from patients with diabetes.
Materials and Methods

Equipment
The Caliper Protein 200 Chip used with the Agilent 2100 Bioanalyzer is a chip-based electrophoretic assay that can separate and detect proteins from 14 to 200 kd. The Agilent 2100 Bioanalyzer, the Protein 200 LabChip kit, and protein chips are distributed by Agilent Technologies. A chip priming station and chip assay software are supplied with the Bioanalyzer. Each chip measures 2.0 × 2.0 × 0.3 in (5.0 × 5.0 × 0.8 cm), and the 2100 Bioanalyzer, which weighs 22 lb (9.9 kg) and measures 6.4 × 16.2 × 11.4 in (16.3 × 41.1 × 29.0 cm), fits easily on a desktop or laboratory bench. The software can run on a Pentium 4 with 1.5 gHz (or similar). The comparison method, an automated immunoturbidimetric assay, which uses antibodies to human albumin, was performed on a Synchron LX20 Pro (Beckman Coulter, Fullerton, CA). The urine creatinine level was determined by the Jaffe method on the Synchron LX20 Pro.
Materials
Each Protein 200 LabChip kit includes 25 protein chips, 4 vials of gel matrix (contains SDS and polydimethylacrylamide), 1 vial of a protein sizing standard or ladder, and 1 vial of a dye concentrate (contains dimethyl sulfoxide).
Before sample preparation, a gel-dye mix, destaining solution, and denaturing solution (as named in the manufacturer's instructions) were prepared. For the gel-dye mix, 25 µL of the dye concentrate was added to a vial of gel matrix. The geldye mix was stable for 4 weeks and enough for 9 chips. The destaining solution was prepared by transferring gel matrix to a spin filter and centrifuging for 15 minutes at room temperature at 2,500g ± 20%. Finally, the denaturing solution we made contained 300 mg/L of 45-kd chicken albumin (stock of 5,000 mg/L) as the internal calibrator, 200 mg/L of 116-kd β-galactosidase (stock of 2,500 mg/L) as the upper molecular marker, and buffer (phosphate-buffered saline). We prepared 200 µL of denaturing solution at a time by using the aforementioned stock solutions (12 µL of chicken albumin, 16 µL of β-galactosidase, and 172 µL of buffer).
To create reducing conditions, 7 µL of β-mercaptoethanol (BME) was added to each 200 µL of denaturing solution. Larger volumes of denaturing solution can be prepared but should contain the same concentrations of chicken albumin, β-galactosidase, and BME. The chicken albumin, β-galactosidase, and BME were obtained from SigmaAldrich, St Louis, MO.
We used 66-kd purified human albumin, also acquired from Sigma-Aldrich, for the linearity study and calibration. Urine samples from 48 patients with diabetes in the VA San Diego Healthcare System, San Diego, CA, were used for comparison of the chip and immunoturbidimetry assays, and all patient information was kept confidential.
Methods
This protein assay, performed on a small chip in conjunction with the Agilent 2100 Bioanalyzer and accompanying software, integrates and automates multiple electrophoretic steps (sample handling, separation, staining, destaining, and detection) and combines it with digital data processing. Each chip has 2 glass layers bonded together, one of which contains photolithographically etched microchannels. There are 16 wells on a chip, 10 for samples.
Before loading a sample onto the chip, the chip's channels were filled with the prepared gel-dye mixture (which contains SDS, dye, and sieving matrix) by pipetting 12 µL of gel-dye mix into one of the wells and applying pressure for 1 minute with a syringe in the chip priming station. The gel-dye mix was also loaded into 3 other wells, destaining solution into 1 well, and sizing ladder into 1 well. For sample preparation, 30 µL of the protein sample was added to 15 µL of the prepared denaturing solution. The sample was heat denatured for 4 minutes in boiling water and then diluted with 630 µL of purified water. (Different volumes of sample, denaturing solution, and water can be used, but the same ratios need to be maintained.)
Up to 10 samples can be loaded onto 1 chip (6 µL per well), and, after sample loading, the chip is placed in the Agilent 2100 Bioanalyzer. The bioanalyzer contains electrodes that touch the samples in each well, creating an electric circuit, which then moves the samples from the wells into the channels. The SDS in the channels surrounds protein in the sample forming SDS-protein micelles that interact with the fluorescent dye. Each sample is then sequentially injected into the separation channel in the center of the chip where sizebased protein separation and detection by a laser fluorescent detection system (630 nm) occur. 21, 22 Analysis of 10 samples takes 25 to 30 minutes, and the results are displayed on a computer screen in a gel-like image, as an electrophoretogram, or in tabular formats, with each protein at its specific separation time based on size and corresponding fluorescence level reflecting protein concentration. Chicken albumin, human albumin, and β-galactosidase separate out at approximately 26, 28, and 33 seconds, respectively.
Samples containing purified human albumin at different dilutions were used for linearity, calibration, and precision analysis. Urine samples from 48 patients with diabetes and urinary albumin levels ranging from 4.0 to 432.8 mg/L by immunoturbidimetry were run on the chip assay, and results were compared with the immunoturbidimetry measurements. The urine creatinine level for each sample was also measured to determine and compare the ACR by each method.
Results
Linearity
Linearity was assessed by using sequential dilutions of the stock human albumin standard. The electrophoretograms obtained from 10 concentrations of human albumin loaded on a single chip are shown in zFigure 1z. The ratio of the human albumin peak area to the chicken albumin peak area (referred to as relative units) was obtained for known human albumin concentrations (7.5, 15, 30, 60, 75, 112.5, 150, 225, 300, 375, and 750 mg/L) with the chip assay. The relative units were then plotted against the known concentrations of human albumin in each sample. We found that for relative units greater than 3.0 (equals 150 mg/L of human albumin), the generated curve was linear zFigure 2Az; and the equation y = 50.6x was used to calculate absolute albumin concentrations in urine samples yielding relative units more than 3.0. For relative units less than 3.0, the data points were nearly linear but were best fit with a polynomial function, which was used to calculate the absolute albumin concentration in urine samples yielding relative units less than 3.0 zFigure 2Bz.
Precision
Evaluation of precision was performed with low, medium, and high concentrations of human albumin. For intrachip precision assessment, 30, 112.5, and 375 mg/L of human albumin were run in 5 sample wells of 1 chip. Also, 75 mg/L of human albumin was run in all 10 wells of 5 different chips. The intrachip coefficients of variation for the 4 albumin concentrations were 0.0% to 4.0% zTable 1z. For interchip precision, concentrations ranging from 7.5 to 375 mg/L were run on 6 chips with coefficients of variation between 4.9% and 13.5% zTable 2z. Finally, day-to-day precision was also assessed and results are shown in zTable 3z.
Comparison Studies
Albumin measurements in urine samples obtained with the P200 chip were compared with albumin concentrations obtained using a conventional immunoassay (immunoturbidimetry). The 48 urine samples were from patients with diabetes and had concentrations of albumin ranging from 4.0 to 432.8 mg/L as measured by immunoturbidimetry. zFigure 3z shows an example of an electrophoretogram from one of the patient samples, which was created by the chip's data analysis software. A graph comparing albumin concentrations detected by immunoturbidimetry vs chip electrophoresis for each sample is shown in zFigure 4z, and the best-fit line yields a correlation of R 2 = 0.917.
The mean albumin concentrations measured by immunoturbidimetry and by chip electrophoresis were 98.2 and 167.5 mg/L, respectively; and for all the urine samples tested, the albumin concentration measured by the chip was greater than that measured by immunoturbidimetry. Because random urine samples were used, the urinary creatinine level for each sample was measured to calculate the ACR. With a definition of microalbuminuria as an ACR between 0.03 and 0.3, 19 samples were normoalbuminuric, 24 were microalbuminuric, and 5 were macroalbuminuric by immunoturbidimetry. For the 19 samples that were classified as normoalbuminuric, the mean ± SD albumin concentration was 19.9 ± 16 mg/L using immunoturbidimetry vs 53.8 ± 28.8 mg/L using the P200 Chip. Keeping the definition of microalbuminuria as an ACR between 0.03 and 0.3, 14 of 19 samples that were normoalbuminuric by immunoassay were actually microalbuminuric by chip electrophoresis. For the 24 samples that were microalbuminuric by immunoturbidimetry, the mean ± SD albumin concentration was 97.0 ± 72.8 mg/L for the immunoassay vs 180.6 ± 126.7 mg/L for chip electrophoresis. Although for these 24 samples the absolute albumin measurement by the chip method was greater than by the immunoassay, they were 
Discussion
The P200 chip assay was proven to be a sensitive and precise method for measuring urinary albumin in this study. With a lower limit of detection of 7.5 mg/L, it offers a good alternative to the currently used immunoassays. Furthermore, we found that the protein chip consistently demonstrated a higher amount of urinary albumin with diabetic urine samples than did immunoturbidimetry. Similar findings were also seen with native PAGE and with HPLC. [16] [17] [18] [19] The measured albumin concentrations by HPLC were 26% and 156% higher than by immunonephelometry in microalbuminuric and normoalbuminuric samples, respectively, and the discrepancy was the greatest at lower levels of urinary albumin. [16] [17] [18] A similar discrepancy was also seen in our study in that 14 patient samples identified as normoalbuminuric by immunoturbidimetry measurements were bumped into the microalbuminuric category with the chip's albumin measurement. However, none of the samples identified as microalbuminuric by immunoturbidimetry were bumped up into the macroalbuminuric category by the chip method.
The higher concentration of urinary albumin detected by nonimmunochemical methods may be due to their ability to measure modified albumin. After glomerular filtration, albumin is modified by lysosomal enzymes, creating some albumin molecules that are intact but no longer immunoreactive owing to "nicking." Grieve et al 15 demonstrated that streptozotocin-induced diabetic rats and control rats contained ACR, albumin/creatinine ratio. * For better comparison of results, the urine samples were divided into 3 groups (normoalbuminuria, microalbuminuria, and macroalbuminuria) based on the immunoturbidimetric albumin measurement and the ACR definition of microalbuminuria. The number of samples classified as normoalbuminuric, microalbuminuric, or macroalbuminuric by immunoturbidimetry and by chip electrophoresis are shown for each group. and the mean ± SD in each group. As shown, more patients are classified as having microalbuminuria when the chip measurement is used. Albumin concentrations are given as mean ± SD.
intact albumin in the urine that could not be detected by immunochemical methods. They found that the immunounreactive albumin excretion rate increased 11-fold after 8 weeks of streptozotocin-induced diabetes as compared with that in control rats. 15 This immunochemically nonreactive form of albumin has also been isolated and purified in urine samples from patients with diabetes. 19 Thus, the renal modification of albumin causes the excretion of intact immunounreactive albumin, which can then be detected only by nonimmunochemical methods. It was once thought that HPLC was the most specific test to measure immunoreactive and immunounreactive forms of intact urinary albumin; however, the accuracy and specificity of size-exclusion HPLC has come into question. Sviridov et al 20 reported that urinary albumin measurements by sizeexclusion HPLC may overestimate the amount of urinary albumin owing to several globulins that elute at the same time as albumin, such as transferrin, α 1 -antitrypsin and α 1 -acid glycoprotein, all of which can also be present in urine. Thus, it seems that HPLC does not specifically detect albumin in urine because its albumin measurement may be including not only intact albumin (immunoreactive and immunounreactive), but also several other urinary globulins. Furthermore, HPLC and conventional PAGE are not practical in most clinical laboratories. HPLC is costly and difficult to perform, and PAGE is labor-intensive and time-consuming. Thus, there is a need to develop a nonimmunologic method that can be easily used in a clinical laboratory setting and detects all forms of intact urinary albumin with good sensitivity and specificity.
As mentioned, the protein chip is sensitive and can detect albumin concentrations as low as 7.5 mg/L. Also, like the other nonimmunochemical techniques, the chip consistently demonstrated a higher albumin concentration than did immunoturbidimetry for all samples tested. Thus, this assay, using a technique equivalent to reducing SDS-PAGE, is likely detecting immunounreactive forms of albumin causing the apparently increased albumin measurements. Although one study showed that reducing-SDS conditions caused a major loss of immunochemically unreactive albumin, 19 we postulate that the reducing conditions used in our study were not as strong, and, thus, some immunounreactive intact albumin remained to be measured.
With electrophoretic methods, other urinary proteins do not seem to be separating out at the same band position as urinary albumin. In a study by Osicka and Comper, 19 3 diabetic urine samples were run by native PAGE, and analysis of the band on the gel that migrated the same distance as the albumin calibrator was shown to contain only albumin by liquid chromatography/mass spectrometry/mass spectrometry. Furthermore, one study that implemented a protein chip technique similar to the method used in the present study demonstrated that purified samples of transferrin, α 1 -antitrypsin, and α 1 -acid glycoprotein were resolved separately and clearly from the albumin peak. 23 Because the traditionally used immunoassays apparently underestimate the amount of intact albumin excreted into urine, methods that can also detect immunounreactive forms of intact albumin may bear some clinical significance. It has been shown that in patients with type 1 and type 2 diabetes, measurement of albumin by HPLC can predict the onset of persistent albuminuria 3.9 and 2.4 years earlier, respectively, than measurement of urinary albumin by radioimmunoassay. 24 In the general population, HPLC measurements correlated better with the presence of peripheral vascular disease and diabetes, although immunoassay measurements correlated better with cardiovascular risk factors. An editorial noted that HPLC is not a readily usable technique in most clinical laboratories and suggested the use of electrophoretic methods to assay urinary proteins. 25 The P200 protein chip may provide such a method in that it is a practical assay that provides a sensitive measurement of microalbuminuria that, in reality, may be more specific and accurate than HPLC. However, more work is needed to establish reference intervals for the chip-based methods and to determine if the values obtained by on-chip electrophoresis correlate with clinically significant outcomes.
